Small Interfering RNA Market Trends

Growth Drivers

Rising Popularity of Personalized Medicine – Small interfering RNA (siRNA) has emerged as a promising possibility for precision therapy in cancer and other diseases as it is highly specific and can be easily generated for multiple target genes.
Growing Geriatric Population- The elderly population is more susceptible to several age-related diseases such as Alzheimer's disease, Huntington's disease, and Parkinson's disease which may benefit from SiRNA treatment.According to estimates, the proportion of the world's population over 60 years old is anticipated to treble from roughly 11 to more than 22% by 2050.

Challenges

High Cost of Developing SiRNA Therapies - Despite their appealing method of action, small interfering RNA therapies confront several hurdles as they are often generated using chemical synthesis, which can be costly if large quantities are required.
Stringent Regulations to Obtain Approvals for SiRNA Therapies
Development of Effective Delivery Methods Can be Challenging

Small Interfering RNA Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	17.2%
Base Year Market Size (2024)	USD 14.97 billion
Forecast Year Market Size (2037)	USD 117.84 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of small interfering RNA is estimated at USD 17.03 billion.

The small interfering RNA market size was valued at USD 14.97 billion in 2024 and is likely to cross USD 117.84 billion by 2037, expanding at more than 17.2% CAGR during the forecast period i.e., between 2025-2037. Rising cases of cancer across the globe and the growing partnerships and collaborations will drive the market growth.

North America industry is likely to account for largest revenue share of 37% by 2037, impelled by increasing spending in healthcare in the region.

The major players in the market include GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis

Small Interfering RNA Market Trends